- Home
- TARS vs CPRI Comparison
TARS vs CPRI Comparison
Compare TARS & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- CPRI
- Stock Information
- Founded
- TARS 2016
- CPRI 1981
- Country
- TARS United States
- CPRI United Kingdom
- Employees
- TARS N/A
- CPRI N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- CPRI Apparel
- Sector
- TARS Health Care
- CPRI Consumer Discretionary
- Exchange
- TARS Nasdaq
- CPRI Nasdaq
- Market Cap
- TARS 1.7B
- CPRI 2.0B
- IPO Year
- TARS 2020
- CPRI 2011
- Fundamental
- Price
- TARS $41.13
- CPRI $19.45
- Analyst Decision
- TARS Strong Buy
- CPRI Buy
- Analyst Count
- TARS 7
- CPRI 11
- Target Price
- TARS $67.14
- CPRI $21.91
- AVG Volume (30 Days)
- TARS 594.1K
- CPRI 3.4M
- Earning Date
- TARS 08-07-2025
- CPRI 08-07-2025
- Dividend Yield
- TARS N/A
- CPRI N/A
- EPS Growth
- TARS N/A
- CPRI N/A
- EPS
- TARS N/A
- CPRI N/A
- Revenue
- TARS $233,674,000.00
- CPRI $4,442,000,000.00
- Revenue This Year
- TARS $122.94
- CPRI N/A
- Revenue Next Year
- TARS $44.14
- CPRI $4.55
- P/E Ratio
- TARS N/A
- CPRI N/A
- Revenue Growth
- TARS 449.03
- CPRI N/A
- 52 Week Low
- TARS $20.08
- CPRI $11.86
- 52 Week High
- TARS $57.28
- CPRI $43.34
- Technical
- Relative Strength Index (RSI)
- TARS 43.15
- CPRI 67.86
- Support Level
- TARS $38.52
- CPRI $16.22
- Resistance Level
- TARS $41.48
- CPRI $18.86
- Average True Range (ATR)
- TARS 1.51
- CPRI 0.66
- MACD
- TARS 0.12
- CPRI 0.19
- Stochastic Oscillator
- TARS 48.21
- CPRI 99.26
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About CPRI Capri Holdings Limited
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. In April 2025, Capri agreed to sell Versace to Prada. John Idol has served as Capri's CEO since 2003.